ODONTOPREV S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.01 BRL | +0.42% |
|
+9.70% | +3.18% |
| Feb. 29 | Transcript : Odontoprev S.A., Q4 2023 Earnings Call, Feb 29, 2024 | |
| Feb. 28 | Odontoprev S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,932 | 7,717 | 6,559 | 4,997 | 6,420 | 6,608 | - | - |
| Enterprise Value (EV) 1 | 8,388 | 6,964 | 5,828 | 4,362 | 5,428 | 5,868 | 6,001 | 5,806 |
| P/E ratio | 31.5 x | 21.4 x | 17.5 x | 10.8 x | 12.6 x | 12.5 x | 12.2 x | 12.1 x |
| Yield | 2.08% | 4.32% | 2.85% | - | - | 6.86% | 7.21% | 7.21% |
| Capitalization / Revenue | 4.98 x | 4.37 x | 3.56 x | 2.55 x | 3 x | 2.87 x | 2.69 x | 2.54 x |
| EV / Revenue | 4.67 x | 3.94 x | 3.16 x | 2.22 x | 2.53 x | 2.55 x | 2.45 x | 2.23 x |
| EV / EBITDA | 20 x | 12.8 x | 10 x | 7.57 x | 8.38 x | 8.25 x | 7.82 x | 7.08 x |
| EV / FCF | 28.2 x | 15.3 x | 13.9 x | 7 x | 17 x | 11.6 x | 12.3 x | 11.1 x |
| FCF Yield | 3.55% | 6.53% | 7.2% | 14.3% | 5.88% | 8.63% | 8.16% | 9.02% |
| Price to Book | 8.04 x | 6.42 x | 5.81 x | 4.21 x | 4.63 x | 4.44 x | 4.09 x | - |
| Nbr of stocks (in thousands) | 582,411 | 583,441 | 572,573 | 553,346 | 552,496 | 552,496 | - | - |
| Reference price 2 | 15.34 | 13.23 | 11.45 | 9.030 | 11.62 | 11.96 | 11.96 | 11.96 |
| Announcement Date | 3/5/20 | 3/4/21 | 2/23/22 | 3/2/23 | 2/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,795 | 1,765 | 1,842 | 1,962 | 2,143 | 2,299 | 2,454 | 2,606 |
| EBITDA 1 | 418.5 | 543.5 | 581.1 | 576 | 647.4 | 711 | 767.4 | 820.6 |
| EBIT 1 | 397.5 | 518.7 | 523.3 | 538.9 | 591.6 | 655.5 | 708.5 | 753.1 |
| Operating Margin | 22.14% | 29.38% | 28.4% | 27.47% | 27.61% | 28.51% | 28.87% | 28.9% |
| Earnings before Tax (EBT) 1 | 405.7 | 520 | 547.2 | 646.3 | 724.4 | 725.9 | 789.1 | 822.4 |
| Net income 1 | 284.8 | 361.1 | 380.4 | 452.2 | 511.4 | 525.1 | 541.8 | 566.3 |
| Net margin | 15.86% | 20.46% | 20.64% | 23.05% | 23.87% | 22.84% | 22.08% | 21.73% |
| EPS 2 | 0.4871 | 0.6181 | 0.6557 | 0.8385 | 0.9256 | 0.9579 | 0.9778 | 0.9870 |
| Free Cash Flow 1 | 297.8 | 454.8 | 419.5 | 623.5 | 319.3 | 506.5 | 489.5 | 523.5 |
| FCF margin | 16.59% | 25.76% | 22.77% | 31.78% | 14.9% | 22.03% | 19.95% | 20.09% |
| FCF Conversion (EBITDA) | 71.16% | 83.68% | 72.2% | 108.25% | 49.32% | 71.24% | 63.79% | 63.8% |
| FCF Conversion (Net income) | 104.57% | 125.94% | 110.3% | 137.88% | 62.44% | 96.46% | 90.35% | 92.44% |
| Dividend per Share 2 | 0.3191 | 0.5711 | 0.3265 | - | - | 0.8210 | 0.8629 | 0.8627 |
| Announcement Date | 3/5/20 | 3/4/21 | 2/23/22 | 3/2/23 | 2/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 467.1 | 469.4 | 471.5 | 481 | 495.4 | 513.7 | 523.8 | 527.7 | 546 | 545.2 | 556 | 557.1 | 570.8 | 572.4 |
| EBITDA 1 | 144.7 | 139.8 | 166.3 | 143.5 | 137.7 | 128.5 | 202 | 147.5 | 156.2 | 141.6 | 199.9 | 159.9 | 161.2 | 151.1 |
| EBIT 1 | 137.2 | 102.7 | 160.6 | 133.1 | 127.8 | 117.4 | 190.5 | 135 | 133.5 | 124.6 | 195.9 | 132 | 107.9 | 176.9 |
| Operating Margin | 29.37% | 21.88% | 34.05% | 27.68% | 25.8% | 22.86% | 36.37% | 25.57% | 24.46% | 22.85% | 35.24% | 23.69% | 18.9% | 30.91% |
| Earnings before Tax (EBT) 1 | - | - | 234.1 | 147.8 | 130.4 | 134 | 246.2 | - | - | 164.4 | 220.3 | 165.5 | 161.2 | 149.5 |
| Net income 1 | 97.8 | 87.18 | 161.5 | 99.57 | 96.19 | 94.95 | 169.6 | 117.2 | 123.4 | 114.6 | 155.2 | 116 | 113.3 | 105.5 |
| Net margin | 20.94% | 18.57% | 34.24% | 20.7% | 19.42% | 18.48% | 32.39% | 22.22% | 22.6% | 21.02% | 27.91% | 20.83% | 19.85% | 18.43% |
| EPS 2 | 0.1727 | 0.1517 | 0.3135 | 0.1790 | 0.1740 | 0.1720 | 0.3070 | 0.2120 | 0.2230 | 0.2074 | 0.2878 | 0.2100 | 0.2051 | 0.1909 |
| Dividend per Share 2 | 0.0236 | 0.0928 | 0.1357 | - | 0.0317 | - | - | - | - | - | 0.1540 | 0.2618 | 0.1995 | 0.1949 |
| Announcement Date | 10/27/21 | 2/23/22 | 4/27/22 | 7/27/22 | 10/26/22 | 3/2/23 | 5/11/23 | 8/9/23 | 11/9/23 | 2/28/24 | - | - | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 544 | 753 | 731 | 634 | 992 | 740 | 607 | 802 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 298 | 455 | 420 | 623 | 319 | 507 | 490 | 524 |
| ROE (net income / shareholders' equity) | 26.6% | 31.2% | 32.8% | 39.3% | 40.7% | 33% | 34% | 34.5% |
| ROA (Net income/ Total Assets) | 16.7% | 19.6% | 19.7% | 22.9% | 25.3% | 20.8% | 20.4% | - |
| Assets 1 | 1,708 | 1,845 | 1,927 | 1,977 | 2,018 | 2,528 | 2,662 | - |
| Book Value Per Share 2 | 1.910 | 2.060 | 1.970 | 2.140 | 2.510 | 2.700 | 2.920 | - |
| Cash Flow per Share 2 | 0.5100 | 0.5200 | 0.8100 | 1.260 | 0.7500 | 1.260 | - | - |
| Capex 1 | 11 | 35.3 | 52 | 71.4 | 95.3 | 94 | 93.5 | 93.5 |
| Capex / Sales | 0.61% | 2% | 2.82% | 3.64% | 4.45% | 4.09% | 3.81% | 3.59% |
| Announcement Date | 3/5/20 | 3/4/21 | 2/23/22 | 3/2/23 | 2/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
11.96
BRL
Average target price
12.6
BRL
Spread / Average Target
+5.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.18% | 1.29B | |
| -15.28% | 5.6B |
- Stock Market
- Equities
- ODPV3 Stock
- Financials Odontoprev S.A.
